Shots:
- GAIA has entered into an exclusive strategic partnership with Daiichi Sankyo Europe to commercialize Lipodia, a digital therapeutic designed to support adults living with hypercholesterolemia, upon regulatory approval
- As per the deal, Daiichi Sankyo Europe will obtain exclusive rights to lipodia, initially covering Germany, with provisions to expand the partnership across major EU markets
- Additionally, GAIA plans to submit Lipodia for reimbursement once pivotal P-III RCT data are available; if approved, it could be prescribed via Germany’s DiGA pathway & reimbursed by statutory health insurance
Ref: Businesswire | Image: GAIA & Daiichi Sankyo | Press Release
Related News: Dumbo Health Introduces a Fully Digital Clinic for Sleep Apnea Treatment Across the US
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
